ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,00%
Bitcoin
67.937,82
0,31%
Brent Oil
81,295
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Veracyte Inc (VCYT)

  7. Veracyte Inc (VCYT) Notícias

VCYT

Veracyte (VCYT)

Veracyte Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VCYT
DataHoraFonteTítuloCódigoCompanhia
30/05/202417:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VCYTVeracyte Inc
28/05/202417:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VCYTVeracyte Inc
22/05/202417:05Business WireVeracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and CancerNASDAQ:VCYTVeracyte Inc
15/05/202418:04Business WireVeracyte to Participate in Upcoming Investor ConferencesNASDAQ:VCYTVeracyte Inc
08/05/202418:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VCYTVeracyte Inc
07/05/202417:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VCYTVeracyte Inc
07/05/202417:05Business WireVeracyte Announces First Quarter 2024 Financial ResultsNASDAQ:VCYTVeracyte Inc
06/05/202417:05Business Wire14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease UnderstandingNASDAQ:VCYTVeracyte Inc
22/04/202418:00Business WireVeracyte to Release First Quarter 2024 Financial Results on May 7, 2024NASDAQ:VCYTVeracyte Inc
22/04/202409:30Business WireNew Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceNASDAQ:VCYTVeracyte Inc
16/04/202409:30Business WireVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024NASDAQ:VCYTVeracyte Inc
29/02/202419:22Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:VCYTVeracyte Inc
29/02/202419:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VCYTVeracyte Inc
29/02/202418:40Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VCYTVeracyte Inc
29/02/202410:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VCYTVeracyte Inc
27/02/202419:55Business WireVeracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN GuidelinesNASDAQ:VCYTVeracyte Inc
22/02/202418:05Business WireVeracyte Announces Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:VCYTVeracyte Inc
21/02/202419:00Business WireVeracyte to Participate in the Raymond James 45th Annual Institutional Investors ConferenceNASDAQ:VCYTVeracyte Inc
08/02/202410:00Business WireVeracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024NASDAQ:VCYTVeracyte Inc
06/02/202410:15Business WireVeracyte Completes Acquisition of C2i GenomicsNASDAQ:VCYTVeracyte Inc
29/01/202418:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VCYTVeracyte Inc
08/01/202410:00Business WireVeracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics PlatformNASDAQ:VCYTVeracyte Inc
12/12/202318:30Business WireVeracyte to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VCYTVeracyte Inc
01/12/202318:05Business WireReal-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to ProgressNASDAQ:VCYTVeracyte Inc
29/11/202310:30Business WireClinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung NodulesNASDAQ:VCYTVeracyte Inc
22/11/202310:30Business WireVeracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023NASDAQ:VCYTVeracyte Inc
07/11/202318:05Business WireVeracyte Announces Third Quarter 2023 Financial ResultsNASDAQ:VCYTVeracyte Inc
07/11/202318:00Business WireVeracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients GloballyNASDAQ:VCYTVeracyte Inc
02/11/202309:15Business WireVeracyte to Participate in the Stephens Annual Investment ConferenceNASDAQ:VCYTVeracyte Inc
27/10/202309:30Business WireVeracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug DevelopmentNASDAQ:VCYTVeracyte Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VCYT

Seu Histórico Recente

BIT
F15599
Vontobel Financial Produ...
EU
CRBP2
Caisse Regionale de Cred...
USOTC
WLLBW
Chord Energy (PK)
COIN
GCNXGBP
GCN PROTOCAL
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados